SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PFE (Pfizer) How high will it go?
PFE 25.20+0.6%3:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: BigKNY3 who wrote (5666)9/23/1998 11:21:00 AM
From: Anthony Wong  Read Replies (1) of 9523
 
09/23 10:31 RESEARCH ALERT - Drug stocks upgraded

NEW YORK, Sept 23 (Reuters) - Southeast Research Partners said on
Wednesday it raised its rating on many large drug companies to buy from
neutral, believing the companies would continue to post double-digit earnings
growth.

-- Analysts Neil Sweig and Le Anne Zhao raised shares of Abbott
Laboratories Inc. <ABT.N>, Bristol-Myers Squibb Co. <BMY.N>, American
Home Products Corp. <AHP.N>, Pfizer <PFE.N>, Eli Lilly and Co.
<LLY.N>, Johnson and Johnson <JNJ.N> and SmithKline Beecham Plc.
<SBH.N> to buy from neutral.

-- "We believe more and more money will move into these above average,
consistently growing shares," Sweig said.

-- Drug companies would stand apart from other multinational firms, posting
solid earnings growth as other companies preannounce shortfalls, he said.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext